Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Amortizatization of Intangibles data on file, last reported at $1.0 million in Q1 2026.

• Amortizatization of Intangibles for Q1 2026 came in at $1.0 million, down 50.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 million (down 73.32% YoY), and the FY2025 annual result was $4.0 million, down 69.23% from the prior year.
• Amortizatization of Intangibles grew to $1.0 million in Q1 2026 per RARE's latest filing, from $516000.0 in the prior quarter.
• Over five years, Amortizatization of Intangibles peaked at $4.1 million in Q4 2023 and troughed at -$1.9 million in Q1 2022.
• A 5-year average of $1.7 million and a median of $2.0 million in 2025 frame the typical range for Amortizatization of Intangibles.
• The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles tumbled 101.49% in 2022, then soared 376.68% in 2023.
• A 5-year view of Amortizatization of Intangibles shows it stood at $1.6 million in 2022, then jumped by 148.85% to $4.1 million in 2023, then fell by 22.5% to $3.2 million in 2024, then plunged by 83.78% to $516000.0 in 2025, then surged by 93.8% to $1.0 million in 2026.
• Business Quant data shows RARE's Amortizatization of Intangibles at $1.0 million in Q1 2026, $516000.0 in Q4 2025, and $704000.0 in Q3 2025.